Brief: Oncternal Therapeutics Announced Pre-Clinical Data From Onct-534, An Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader
05/10/2021 21:07
Oct 5 (Reuters) - Oncternal Therapeutics Inc ONCT.O :
* ONCTERNAL THERAPEUTICS ANNOUNCED PRE-CLINICAL DATA FROM
ONCT-534, AN ANDROGEN RECEPTOR N-TERMINAL-DOMAIN-BINDING SMALL
MOLECULE DEGRADER, WAS ACCEPTED FOR VIRTUAL POSTER PRESENTATION
AT AACR-NCI-EORTC VIRTUAL INTERNATIONAL CONFERENCE ON MOLECULAR
TARGETS AND CANCER THERAPEUTICS
Source text for Eikon: ID:nGNX5lHDbR
Further company coverage: ONCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncternal Therapeutics
See all newsOncternal Therapeutics Inc expected to post a loss of $3.19 a share - Earnings Preview
Brief: Oncternal Therapeutics Workforce Reduction Of About 10 Employees
U.S. STOCKS ON THE MOVE-Unity Software, Viking Holdings, Adobe
U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Warner Bros Discovery
Oncternal hits record low on plans to scrap studies, explore strategic alternatives;